LTR Pharma (ASX:LTP) has dosed the first patients in the phase two pharmacokinetic study of Spontan, its rapid-acting intranasal spray to treat erectile dysfunction, signaling the shift from recruitment to active data collection, according to a Thursday Australian bourse filing.

The study is evaluating single and multiple dose pharmacokinetics in around 27 healthy male participants across three cohorts, with about half aged 65 or older in line with US Food and Drug Administration geriatric guidance, per the filing.

The study remains on track, with initial data expected in the second quarter, the filing added.

The company's shares rose 4% in recent Thursday trade.